Last reviewed · How we verify
Tazarotene Topical Gel
Tazarotene Topical Gel, marketed by Assiut University, is a dermatological treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, though specific details on its mechanism and primary indication are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Tazarotene Topical Gel |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (PHASE2)
- Excimer Laser With Topical Agents in Psoriasis Vulgaris (PHASE4)
- Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars (PHASE2, PHASE3)
- Efficacy of Tazarotene in Treatment of Verruca Plana (PHASE2)
- Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis (NA)
- Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring (NA)
- A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris (PHASE1)
- Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene Topical Gel CI brief — competitive landscape report
- Tazarotene Topical Gel updates RSS · CI watch RSS
- Assiut University portfolio CI